Related Experiment Video

Updated: May 2, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model

K Geisler1, A Reischer1, I Kroeger1

  • 1Department of Internal Medicine 5, Hematology/Oncology, University of Erlangen-Nürnberg, Erlangen, Germany.

Oncology Reports
|March 15, 2014
PubMed

Insights

Nilotinib combined with interleukin-2 (IL-2) demonstrates superior antitumor activity by enhancing natural killer (NK) cell responses. This combination therapy shows promise for cancer immunotherapy, particularly involving IFN-γ-producing NK cells.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Cancer chemotherapeutics and immune modulatory drugs, like tyrosine kinase inhibitors (TKIs), can enhance the immune system's tumor-killing capacity.
  • Previous studies showed benefits of combining interleukin-2 (IL-2) with the TKI imatinib, highlighting the role of natural killer (NK) cells.

Purpose of the Study:

  • To compare the antitumor and immunological effects of imatinib and nilotinib when combined with IL-2.
  • To investigate the specific mechanisms underlying the efficacy of these TKI-IL-2 combinations in a preclinical cancer model.

Main Methods:

  • Utilized a murine B16F10 melanoma model to assess antitumor activity in vivo.
  • Employed immunodeficient mice (Rag2γc-/-) and NK cell-depleted mice to determine the role of lymphocytes and NK cells.
  • Used flow cytometry to analyze immune cell populations and measured interferon-gamma (IFN-γ) production.
  • Assessed therapeutic effects in IFN-γ knockout (IFN-γ-/-) mice.

Main Results:

  • Both imatinib and nilotinib exhibited antitumor activity, but the nilotinib-IL-2 combination proved superior.
  • The therapeutic benefit of nilotinib was significantly reduced in immunodeficient and NK cell-depleted mice.
  • Nilotinib and IL-2 treatment led to a notable increase in IFN-γ-producing CD27+ NK cells.
  • The antitumor effect of nilotinib/IL-2 was abolished in IFN-γ-/- mice, underscoring the critical role of IFN-γ.

Conclusions:

  • Nilotinib in combination with IL-2 demonstrates significant antitumor efficacy.
  • This combination therapy relies on the activation of IFN-γ-producing CD27+ NK cells.
  • Findings provide crucial insights for developing novel immunotherapeutic strategies using TKIs.

More Related Videos

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.1K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

5.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K